SERTAD1 (SERTA domain-containing protein 1), also known as TRIP-Br1 or p34SEI-1. is a nuclear protein involved in cell cycle regulation and transcriptional control. It belongs to the SERTA protein family, characterized by a conserved SERTA domain. SERTAD1 functions as a transcriptional co-regulator, interacting with proteins like E2F and pRB to modulate the expression of genes critical for G1/S phase transition. It stabilizes Cyclin D1-CDK4 complexes, promoting cell cycle progression, and has been implicated in oncogenesis due to its role in dysregulated proliferation.
Antibodies targeting SERTAD1 are essential tools for studying its expression, localization, and interactions. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate SERTAD1's involvement in cancers (e.g., breast, colorectal) and other pathologies. Research has linked SERTAD1 overexpression to tumor aggressiveness, metastasis, and poor prognosis, making it a potential biomarker or therapeutic target.
These antibodies also aid in exploring SERTAD1's non-cancer roles, including its regulatory effects on apoptosis and differentiation. Validation of SERTAD1 antibodies for specificity and cross-reactivity is crucial, given its homology with other SERTA family members (SERTAD2-4). Commercial antibodies are typically raised against epitopes within its unique N-terminal region to ensure selectivity. Overall, SERTAD1 antibodies are pivotal in unraveling its dual roles in normal physiology and disease.